The central nervous system (CNS) regulates cognition, behavior, and physiological functions. Neurological disorders such as Alzheimer's disease, Parkinson's disease, depression, and schizophrenia continue to drive demand for effective CNS therapies. However, CNS drug development remains one of the most challenging areas in pharmaceutical research because of complex disease mechanisms and the difficulty of delivering drugs into the brain.
Biological Barriers to Brain Drug Delivery
The greatest challenge in CNS drug development is achieving sufficient drug exposure in the brain. Two physiological barriers tightly regulate the movement of compounds into the CNS:
Blood-Brain Barrier (BBB): Formed by tightly connected brain endothelial cells, the BBB blocks most circulating compounds from entering brain tissue. While small lipophilic molecules can often diffuse across the BBB, many hydrophilic or highly protein-bound drugs cannot.
Blood-Cerebrospinal Fluid Barrier (BCSFB): Located in the choroid plexus, the BCSFB regulates exchange between the bloodstream and cerebrospinal fluid (CSF), further limiting the entry of large molecules and peptides.
Because of these barriers, optimizing brain exposure is a critical objective during CNS drug discovery.
Evaluating Brain Exposure
Drug exposure in the CNS is typically assessed by measuring drug concentrations in plasma, brain tissue, and CSF. Since directly measuring intracellular drug concentrations is difficult, researchers often use CSF or brain interstitial fluid as surrogate indicators.
Several key parameters are commonly used:
Kp,brain: Measures total drug distribution between brain tissue and plasma.
Kp,uu: Represents the ratio of free drug concentrations in the brain and plasma, providing a more accurate assessment of BBB penetration.
CSF concentration: Often serves as an indirect indicator of free drug exposure in the brain.
Among these, Kp,uu is generally considered the most informative parameter because it reflects both passive diffusion and transporter activity.
Common Methods for BBB Assessment
A combination of in vitro and in vivo approaches is typically used during CNS drug discovery.
Animal pharmacokinetic studies remain the primary method for determining drug concentrations in plasma, brain tissue, and CSF.
PAMPA-BBB assays evaluate passive diffusion across an artificial membrane and are widely used for high-throughput screening.
Cell-based BBB models, including MDCK-MDR1 and Caco-2 systems, are commonly used to investigate transporter-mediated drug movement, particularly P-glycoprotein (P-gp) efflux.
In situ brain perfusion is considered the reference method for directly measuring BBB permeability, although its technical complexity limits routine use.
The Importance of P-gp
P-glycoprotein (P-gp) is one of the major efflux transporters at the BBB. Drugs that are P-gp substrates are actively transported out of the brain, reducing therapeutic exposure. Early evaluation of P-gp interactions can help optimize compound design and improve CNS penetration.
Prisys Biotech DMPK Services
Prisys Biotech provides comprehensive DMPK support for CNS drug development, including in vivo pharmacokinetic studies, ADMET evaluation, toxicokinetic studies, and customized tissue distribution analyses. Our experienced team supports multiple animal species, administration routes, sampling strategies, and experimental designs to help accelerate preclinical CNS drug discovery.
